Actinogen CEO Steven Gourlay Boosts Shareholding Through Option Exercise

Actinogen Medical ( (AU:ACW) ) just unveiled an update.

Actinogen Medical has disclosed a change in director Dr Steven Gourlay’s interests following the exercise of unlisted options into fully paid ordinary shares. Gourlay converted a total of 2,442,647 unlisted options, increasing both his direct and indirect shareholdings while reducing his unlisted option holdings, in a transaction valued at $91,599.26.

Following the transaction, Gourlay now holds a larger equity stake through direct and trust-related holdings, with his remaining exposure shifted more towards ordinary shares and listed options rather than unlisted options. The move modestly simplifies the company’s capital structure related to his incentives and signals a greater alignment of the CEO’s interests with those of ordinary shareholders through increased outright share ownership.

The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an Australia-listed biotechnology company focused on developing therapies using novel approaches, including treatments that may be supported through employee equity participation. The company’s capital structure includes fully paid ordinary shares, listed options, and unlisted options that form part of director and executive incentive arrangements.

Average Trading Volume: 2,837,323

Technical Sentiment Signal: Buy

Current Market Cap: A$168.7M

See more insights into ACW stock on TipRanks’ Stock Analysis page.